Danny Reinberg, Ph.D.

Danny Reinberg, Ph.D., a biochemistry and molecular mechanisms expert, is currently the only Howard Hughes Medical Institute (HHMI) Investigator in Florida — a prestigious designation that indicates the powerful impact of his studies. He is also the associate director of faculty training and recruitment and a distinguished professor at the Miller School of Medicine. Dr. Reinberg is part of an elite group of 260 HHMI scientists representing only 58 U.S. research institutions who tackle difficult research questions that may take years to answer. 

Aman Chauhan, M.D.

Aman Chauhan, M.D., assumed leadership of Sylvester’s Neuroendocrine Tumor Program with a vision to revolutionize patient outcomes and advance the understanding of this often-overlooked cancer. He aspires to transform the landscape of neuroendocrine cancer care through leading-edge research and innovative treatments, serving international patients seeking pioneering therapies in the field. Through his collaborative efforts, he is working to redefine the standard of care for neuroendocrine cancer. With a steadfast focus on research, he continues to pave the way for the next generation of therapeutic interventions. 

Nima Sharifi, M.D.

Nima Sharifi, M.D., joined Sylvester as a medical oncologist and physician-scientist and was also named scientific director of the Miller School of Medicine’s Desai Sethi Urology Institute. Dr. Sharifi works collaboratively with Sylvester to treat genitourinary cancers and conduct the high-level research, improving outcomes for patients. While his area of focus is on prostate cancer, his expertise and leadership will drive impactful research beyond genitourinary cancers. Dr. Sharifi and his team are bridging laboratory research on prostate, kidney and bladder cancers to human studies.